Point72 Asset Management
CNTX icon

Point72 Asset Management’s Context Therapeutics CNTX Stock Holding History

Point72 Asset Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150K Buy
57,231
+4,530
+9% +$10.6K ﹤0.01% 3567
2025
Q4 		$77.5K Buy
+52,701
New +$61.6K ﹤0.01% 3758

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asset Management's CNTX Position: Q1 2026 in Review

Point72 Asset Management increased its Context Therapeutics (CNTX) stake by 8.6% in Q1 2026, buying an estimated $10.6K and bringing the position to 57,231 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #3567.

Point72 Asset Management first reported a position in CNTX in Q4 2025 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Point72 Asset Management held 57,231 shares of Context Therapeutics worth $150K as of Q1 2026.
  • Point72 Asset Management bought 4,530 Context Therapeutics shares in Q1 2026, an estimated $10.6K.
  • Context Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3567 holding.
  • Point72 Asset Management first reported a position in Context Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.